28284864|t|Development of a novel near-infrared fluorescent theranostic combretastain A-4 analogue, YK-5-252, to target triple negative breast cancer
28284864|a|The treatment of triple negative breast cancer (TNBC) is a significant challenge to cancer research. The lack of hormone receptors limits the treatment options available to patients with this diagnosis, forcing them to endure prolonged radiation and chemotherapy. Anti-angiogenesis is a chemotherapeutic strategy that targets the vasculature of tumors. Combretastatin A-4 (CA-4) is a well-known vasculature - disrupting agent, which has been shown to effectively kill a variety of cancers through inhibition of tubulin polymerization. Due to its toxicity, small molecule analogues of CA-4 have been sought out. We have designed a novel dual action CA-4 prodrug, YK-5-252, which releases the drug through a disulfide bond cleavage mechanism and contains a near-infrared (NIR) fluorophore, which allows fluorescence monitoring of cleavage. This disulfide linkage causes CA-4 to become effective only when released by glutathione (GSH) reducing the toxicity of the drug while simultaneously releasing the NIR fluorophore. Therefore the prodrug, YK-5-252, represents a novel CA-4 analogue which has reduced toxicity and can be used for theranostics imaging.
28284864	17	22	novel	T080	C0205314
28284864	23	36	near-infrared	T070	C1289901
28284864	37	48	fluorescent	T070	C0016315
28284864	49	60	theranostic	T091	C4046052
28284864	61	78	combretastain A-4	T109,T121	C0056154
28284864	79	87	analogue	T104	C0002776
28284864	89	97	YK-5-252	T121	C1254351
28284864	109	138	triple negative breast cancer	T191	C3539878
28284864	143	152	treatment	T061	C0087111
28284864	156	185	triple negative breast cancer	T191	C3539878
28284864	187	191	TNBC	T191	C3539878
28284864	223	238	cancer research	T062	C1516225
28284864	252	269	hormone receptors	T116,T192	C0019929
28284864	281	290	treatment	T061	C0087111
28284864	312	320	patients	T101	C0030705
28284864	331	340	diagnosis	T033	C0011900
28284864	375	384	radiation	T061	C1522449
28284864	389	401	chemotherapy	T061	C3665472
28284864	403	420	Anti-angiogenesis	T061	C0281318
28284864	469	480	vasculature	T017	C3714653
28284864	484	490	tumors	T191	C0027651
28284864	492	510	Combretastatin A-4	T109,T121	C0056154
28284864	512	516	CA-4	T109,T121	C0056154
28284864	534	545	vasculature	T017	C3714653
28284864	620	627	cancers	T191	C0006826
28284864	636	646	inhibition	T052	C3463820
28284864	650	657	tubulin	T116,T123	C0041348
28284864	658	672	polymerization	T067	C0314672
28284864	685	693	toxicity	T037	C0600688
28284864	710	719	analogues	T104	C0002776
28284864	723	727	CA-4	T109,T121	C0056154
28284864	769	774	novel	T080	C0205314
28284864	787	791	CA-4	T109,T121	C0056154
28284864	792	799	prodrug	T120	C0033262
28284864	801	809	YK-5-252	T121	C1254351
28284864	830	834	drug	T121	C1254351
28284864	845	859	disulfide bond	T044	C0813982
28284864	860	868	cleavage	T067	C0596311
28284864	869	878	mechanism	T169	C0441712
28284864	894	907	near-infrared	T070	C1289901
28284864	909	912	NIR	T070	C1289901
28284864	914	925	fluorophore	T121,T130	C0598447
28284864	940	952	fluorescence	T070	C0016315
28284864	967	975	cleavage	T067	C0596311
28284864	982	999	disulfide linkage	T044	C0813982
28284864	1007	1011	CA-4	T109,T121	C0056154
28284864	1054	1065	glutathione	T116,T123	C0017817
28284864	1067	1070	GSH	T116,T123	C0017817
28284864	1085	1093	toxicity	T037	C0600688
28284864	1101	1105	drug	T121	C1254351
28284864	1141	1144	NIR	T070	C1289901
28284864	1145	1156	fluorophore	T121,T130	C0598447
28284864	1172	1179	prodrug	T120	C0033262
28284864	1181	1189	YK-5-252	T121	C1254351
28284864	1204	1209	novel	T080	C0205314
28284864	1210	1214	CA-4	T109,T121	C0056154
28284864	1215	1223	analogue	T104	C0002776
28284864	1242	1250	toxicity	T037	C0600688
28284864	1271	1283	theranostics	T091	C4046052
28284864	1284	1291	imaging	T060	C0079595